Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option to Purchase Additional Shares

Business Wire January 27, 2020

Zymeworks Announces Pricing of $279.0 Million Public Offering

Business Wire January 22, 2020

Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

Business Wire January 21, 2020

Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities

Business Wire January 13, 2020

Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)

Business Wire January 12, 2020

Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020

Business Wire January 7, 2020

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

Business Wire November 22, 2019

Zymeworks Announces Selection of ZW25 Abstract for Mini Oral Presentation at the European Society for Medical Oncology Asia (ESMO Asia) Congress

Business Wire November 18, 2019

Zymeworks Files Automatic Shelf Registration Statement and Enters into At-The-Market Equity Offering Sales Agreement

Business Wire November 5, 2019

Zymeworks Reports 2019 Third Quarter Financial Results

Business Wire November 5, 2019

Zymeworks to Present at Stifel 2019 Healthcare Conference

Business Wire November 4, 2019

Zymeworks Announces Phase 1 Data for ZW25 in Combination with Chemotherapy in Advanced Gastroesophageal Adenocarcinoma at AACR-NCI-EORTC International Conference

Business Wire October 28, 2019

Zymeworks Appoints Chief People Officer

Business Wire October 16, 2019

Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at European Society for Medical Oncology (ESMO) Congress

Business Wire September 28, 2019

Zymeworks to Participate in Upcoming Investor Conferences

Business Wire August 28, 2019

Zymeworks Reports 2019 Second Quarter Financial Results

Business Wire August 2, 2019

Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks

Business Wire July 16, 2019

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option to Purchase Additional Shares

Business Wire June 24, 2019

Zymeworks Announces Pricing of $175.0 Million Public Offering

Business Wire June 19, 2019

Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

Business Wire June 18, 2019